CASTLE BIOSCIENCES INC

NASDAQ: CSTL (Castle Biosciences, Inc.)

Last update: 27 Nov, 2025, 7:57AM

39.94

0.01 (0.03%)

Previous Close 39.93
Open 39.93
Volume 472,737
Avg. Volume (3M) 412,321
Market Cap 1,165,795,072
Price / Sales 3.28
Price / Book 2.41
52 Weeks Range
14.59 (-63%) — 40.51 (1%)
Earnings Date 3 Nov 2025
Profit Margin -1.46%
Operating Margin (TTM) -31.74%
Diluted EPS (TTM) -0.190
Quarterly Revenue Growth (YOY) 20.60%
Total Debt/Equity (MRQ) 5.87%
Current Ratio (MRQ) 9.37
Operating Cash Flow (TTM) 65.67 M
Levered Free Cash Flow (TTM) 44.64 M
Return on Assets (TTM) -1.80%
Return on Equity (TTM) -1.20%

Market Trend

Short Term Medium Term
Industry Diagnostics & Research (US) Bullish Bullish
Diagnostics & Research (Global) Bullish Bullish
Stock Castle Biosciences, Inc. Bearish Bullish

AIStockmoo Score

-0.6
Analyst Consensus 2.0
Insider Activity NA
Price Volatility -5.0
Technical Moving Averages 0.0
Technical Oscillators 0.5
Average -0.63

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
CSTL 1 B - - 2.41
SHC 5 B - 86.40 9.70
WGS 4 B - 1,276.73 13.08
TWST 2 B - - 4.50
NEOG 2 B - - 0.720
CDNA 1 B - 14.95 3.12

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Sector Healthcare
Industry Diagnostics & Research
Investment Style Small Core
% Held by Insiders 2.98%
% Held by Institutions 93.02%
52 Weeks Range
14.59 (-63%) — 40.51 (1%)
Price Target Range
41.00 (2%) — 50.00 (25%)
High 50.00 (Canaccord Genuity, 25.19%) Buy
50.00 (BTIG, 25.19%) Buy
Median 46.50 (16.43%)
Low 41.00 (Baird, 2.65%) Buy
Average 46.00 (15.17%)
Total 4 Buy
Avg. Price @ Call 37.66
Firm Date Target Price Call Price @ Call
Guggenheim 05 Jan 2026 43.00 (7.66%) Buy 39.00
Canaccord Genuity 22 Dec 2025 50.00 (25.19%) Buy 41.39
BTIG 12 Dec 2025 50.00 (25.19%) Buy 38.63
05 Nov 2025 38.00 (-4.86%) Buy 33.57
Baird 04 Nov 2025 41.00 (2.65%) Buy 31.63

No data within this time range.

Date Type Details
19 Dec 2025 Announcement Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Dec 2025 Announcement Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
12 Dec 2025 Announcement Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
09 Dec 2025 Announcement Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
17 Nov 2025 Announcement Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
14 Nov 2025 Announcement New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
11 Nov 2025 Announcement Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
03 Nov 2025 Announcement Castle Biosciences Reports Third Quarter 2025 Results
03 Nov 2025 Announcement Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
28 Oct 2025 Announcement Castle Biosciences to Participate in Upcoming Investor Conferences
26 Oct 2025 Announcement New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
24 Oct 2025 Announcement New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
13 Oct 2025 Announcement Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria